Paul Tudor Jones’s Calithera Biosciences, Inc CALA Stock Holding History

Paul Tudor Jones’s Portfolio CALA Stock Details CALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,348	Closed	-$27K	–	2656
2022 Q1	$27K	Hold	3,348	–	–	﹤0.01%	1892
2021 Q4	$45K	Buy	3,348 +2,001	+149%	+$50.3K	﹤0.01%	2274
2021 Q3	$59K	Buy	+1,347	New	+$58.1K	﹤0.01%	2378
2021 Q2	–	Sell	-3,988	Closed	-$193K	–	2114
2021 Q1	$193K	Buy	3,988 +3,019	+312%	+$176K	﹤0.01%	1441
2020 Q4	$95K	Buy	+969	New	+$84.9K	﹤0.01%	1271
2019 Q3	–	Sell	-4,970	Closed	-$388K	–	1423
2019 Q2	$388K	Buy	+4,970	New	+$564K	0.01%	792
2018 Q3	–	Sell	-604	Closed	-$60K	–	1326
2018 Q2	$60K	Sell	604 -1,014	-63%	-$115K	﹤0.01%	1000
2018 Q1	$204K	Sell	1,618 -147	-8%	-$22.9K	0.01%	863
2017 Q4	$295K	Buy	+1,765	New	+$452K	0.01%	807
2017 Q2	–	Sell	-4,986	Closed	-$1.15M	–	1468
2017 Q1	$1.15M	Buy	+4,986	New	+$861K	0.04%	328

Other funds holding CALA

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's CALA Position: Q2 2022 in Review

Paul Tudor Jones sold out of Calithera Biosciences, Inc (CALA) in Q2 2022, closing a stake of 3,348 shares — an estimated $27K sold.

Paul Tudor Jones first reported a position in CALA in Q1 2017 and held it in 10 quarters. The position peaked at $1.15M in Q1 2017. 28 funds tracked by Wall St. Rank hold CALA as of Q2 2022.

Paul Tudor Jones reported no remaining Calithera Biosciences, Inc position as of Q2 2022 after selling out during the quarter.
Paul Tudor Jones sold 3,348 Calithera Biosciences, Inc shares in Q2 2022, an estimated $27K.
Paul Tudor Jones first reported a position in Calithera Biosciences, Inc in Q1 2017 and held it in 10 quarters.
Paul Tudor Jones's Calithera Biosciences, Inc position peaked at $1.15M in Q1 2017.
28 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2022.

Based on Tudor Investment Corp's 13F filing for Q2 2022, filed 15 Aug 2022.